Aktualitet

Brataj publishes study: Chinese vaccine effective against Brazilian variant of virus

Brataj publishes study: Chinese vaccine effective against Brazilian variant of

The Chinese vaccine, Coronavac from the Sinovac company is also effective against the highly contagious Brazilian variant of the virus. The head of the National Emergency, Skënder Brataj has published a study with data that prove it.

"In the interim analysis, the efficacy of CoronaVac was 50% in preventing the symptomatic disease of Covid-19," says the preliminary study report. Of particular importance is the fact that this percentage is only after the first dose ", quotes part of the study Dr. Brataj.

The study was conducted in Brazil with 67,718 health workers in Manaus.

CoronaVac is a vaccine made up of inactivated viruses, which means it contains all parts of the virus. This can generate a more complete immune response than other vaccines that use only part of the Spike protein (the protein used by the coronavirus to enter cells). The vaccine is applied in two doses, with an interval of 14 to 28 days.

193 thousand doses of vaccines have arrived in Albania from Sinovac, with which the vaccination process continues for the elderly over 70, field journalists and operators, as well as police officers.

Below you have the full post by Skënder Brataj:

Like any virus, bacteria, parasite or disease, you SarsCov 2 can not!
Good news on the CoronaVac vaccine!
The latest study in Brazil!
CoronaVac is effective against the Brazilian variant of Covid-19 P.1.
The study was conducted with 67.7 thousand health workers in the city of Manaus
Posted on 07/04/2021.
By Elaine Patricia Cruz - Agencia Brasil - São Paulo
The CoronaVac vaccine is an immunizer manufactured by the Butantan Institute and the Chinese pharmaceutical company Sinovac. It is 50% effective against variant P.1 of Covid-19, the Brazilian variant, which appeared in the city of Manaus in 2020 and which already prevails in some Brazilian states. Efficacy in disease prevention was confirmed 14 days after the application of the first dose.
The study was conducted with 67,718 health workers in Manaus and published by the Vebra Covid-19 group, which brings together researchers from national and international institutions, the Amazon state health departments of São Paulo and the municipal health departments in Manaus and San Paolo, supported by the Pan American Health Organization (OPS).
Research has not yet evaluated the effectiveness after the application of the second dose, which will come out in the coming weeks. In the interim analysis, the efficacy of CoronaVac was 50% in preventing the symptomatic disease of Covid-19, says the preliminary study report. Of particular importance is the fact that this percentage is only after the first dose!
These results are very encouraging because CoronaVac remains effective in reducing the risk of symptomatic disease in a scenario with a prevalence above 50% of the Brazilian variant P.1, the study notes. These findings support the continued use of this vaccine in Brazil and other countries with the same circulating variant, the researchers said.
For the director of the Butantan Institute, Dimas Covas, the field study is showing the effectiveness of the vaccine, and its effectiveness has been determined by clinical trials.
If after the first dose the effectiveness is 50%, it is expected that after the second dose this percentage will increase significantly, said Covas. He cited another study, done in Chile, where CoronaVac is being administered to the population. So far, a reduction in hospitalizations and deaths of people over the age of 70 has been demonstrated.
CoronaVac is a vaccine made up of inactivated viruses, which means it contains all parts of the virus. This can generate a more complete immune response than other vaccines that use only part of the Spike protein (the protein used by the coronavirus to enter cells). The vaccine is applied in two doses, with an interval of 14 to 28 days.
https://agenciabrasil.ebc.com.br
Dr. Skender Brataj

* Tiranapost.al.